| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w11875 |
| 来源ID | Working Paper 11875 |
| The Future of Drug Development: The Economics of Pharmacogenomics | |
| John A. Vernon; W. Keener Hughen | |
| 发表日期 | 2005-12-19 |
| 出版年 | 2005 |
| 语种 | 英语 |
| 摘要 | This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance of uncertainty around how PG will impact the future landscape of pharmaceutical and biological R&D, we identify several likely outcomes. We conclude PG has the potential to significantly reduce both expected drug development costs (via higher probabilities of technical success, shorter clinical development times, and smaller clinical trials) and returns. The impact PG has on expected returns is partially mitigated by higher equilibrium prices, expedited product launches, and longer effective patent lives. Our conclusions are, of course, accompanied by numerous caveats. |
| 主题 | Health, Education, and Welfare ; Health |
| URL | https://www.nber.org/papers/w11875 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/569526 |
| 推荐引用方式 GB/T 7714 | John A. Vernon,W. Keener Hughen. The Future of Drug Development: The Economics of Pharmacogenomics. 2005. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w11875.pdf（302KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
